These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33129491)

  • 21. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study.
    Walley RJ; Smith CL; Gale JD; Woodward P
    Pharm Stat; 2015; 14(3):205-15. PubMed ID: 25865949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian methods for pilot studies.
    Willan AR; Thabane L
    Clin Trials; 2020 Aug; 17(4):414-419. PubMed ID: 32297539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.
    Pedroza C; Tyson JE; Das A; Laptook A; Bell EF; Shankaran S;
    Trials; 2016 Jul; 17(1):335. PubMed ID: 27450203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
    Turkoz I; Sobel M; Alphs L
    Pharm Stat; 2019 Jan; 18(1):22-38. PubMed ID: 30221459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
    Yu Z; Ramakrishnan V; Meinzer C
    J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical Bayesian design and analysis for drug and device clinical trials.
    Hobbs BP; Carlin BP
    J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
    Zhan T; Zhang H; Hartford A; Mukhopadhyay S
    J Biopharm Stat; 2020 Sep; 30(5):821-833. PubMed ID: 32297825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
    Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
    Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.
    Chen MH; Ibrahim JG; Amy Xia H; Liu T; Hennessey V
    Stat Med; 2014 Apr; 33(9):1600-18. PubMed ID: 24343859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive checking for Bayesian interim analyses in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Sep; 29(5):740-50. PubMed ID: 18571477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 2: Statistical considerations.
    Ball G; Piller LB
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S5-7. PubMed ID: 21664986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian approach in design and analysis of pediatric cancer clinical trials.
    Ye J; Reaman G; De Claro RA; Sridhara R
    Pharm Stat; 2020 Nov; 19(6):814-826. PubMed ID: 32537913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.
    Shen W; Ning J; Yuan Y
    Stat Med; 2015 Jun; 34(13):2104-15. PubMed ID: 25756852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.